Akari Therapeutics (AKTX) vs Cocrystal Pharma (COCP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cocrystal Pharma (COCP) has outperformed Akari Therapeutics (AKTX) over the past year, losing 14.4% versus a loss of 80.1%. Over five years, COCP leads with a -90.5% price change compared with -99.4% for AKTX. Cocrystal Pharma is the larger company by market cap ($20.6 million vs $18.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | COCP |
|---|---|---|
| Share price | $8.13 | $1.07 |
| Market cap | $18.58M | $20.61M |
| 1-day change | -5.74% | 0.00% |
| YTD return | -29.67% | +9.18% |
| 1-year return | -80.07% | -14.40% |
| 5-year return | -99.38% | -90.51% |
| EPS (TTM) | $0.00 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.00 | $2.03 |
| 52-week low | $3.02 | $0.76 |
| Distance from 52-week high | -79.67% | -47.29% |
| Analyst consensus | none | none |
| Avg. price target upside | +213.65% | +741.12% |
| Average volume | 61.08K | 56.00K |
| Shares outstanding | 2.29M | 19.26M |
| Employees | 5 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COCP has outperformed AKTX by 65.7 percentage points over the past year.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Cocrystal Pharma
COCP stock →Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
AKTX vs COCP FAQ
Which is bigger, Akari Therapeutics or Cocrystal Pharma?
Cocrystal Pharma (COCP) is larger, with a market capitalization of $20.61M compared with $18.58M for Akari Therapeutics (AKTX).
Which stock has performed better over the past year, AKTX or COCP?
COCP returned -14.40% over the past 12 months, compared with -80.07% for AKTX (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Cocrystal Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.